The effects of postseason break on knee biomechanics and lower extremity EMG in a stop-jump task: implications for ACL injury

The effects of training on biomechanical risk factors for anterior cruciate ligament (ACL) injuries have been investigated, but the effects of detraining have received little attention. The purpose of this study was to evaluate the effects of a one-month postseason break on knee biomechanics and lower extremity electromyography (EMG) during a stop-jump task. A postseason break is the phase between two seasons when no regular training routines are performed. Twelve NCAA female volleyball players participated in two stop-jump tests before and after the postseason break. Knee kinematics, kinetics, quadriceps EMG, and hamstring EMG were assessed. After one month of postseason break, the players demonstrated significantly decreased jump height, decreased initial knee flexion angle, decreased knee flexion angle at peak anterior tibial resultant force, decreased prelanding vastus lateralis EMG, and decreased prelanding biceps femoris EMG as compared with prebreak. No significant differences were observed for frontal plane biomechanics and quadriceps and hamstring landing EMG between prebreak and postbreak. Although it is still unknown whether internal ACL loading changes after a postseason break, the more extended knee movement pattern may present an increased risk factor for ACL injuries

New verified nonindigenous amphibians and reptiles in Florida, 1976 through 2015, with a summary of over 152 years of introductions

More nonindigenous species occur in Florida, USA, than any other region worldwide and may threaten many of Florida’s natural resources. The frequency of new reports mandates the need for regular updates. Herein, we use photographic and specimen vouchers in addition to literature records to provide updated information on verified nonindigenous amphibians and reptiles in Florida. Between our most recent summary in 2012 and the end of 2015, 38 additional species are known to have been intercepted (n = 2) or introduced (n = 36). We also update the invasion stage of seven species previously reported from Florida and report that five additional taxa are now established. In total, 191 independent known introductions of 180 herpetofaunal taxa led to the establishment of 63 taxa. This suggests that one in three introduced herpetofaunal species becomes established in Florida. The pet trade represents the most  common introduction pathway among these species animal importer in Hollywood, Broward County, is the probable source for introduction of a quarter of all herpetofauna introduced to Florida

New Verified Nonindigenous Amphibians and Reptiles in Florida through 2015, with a Summary of More Than 152 Years of Introductions.

More nonindigenous species occur in Florida, USA, than any other region worldwide and may threaten many of Florida’s natural resources. The frequency of new reports mandates the need for regular updates. Herein, we use photographic and specimen vouchers in addition to literature records to provide updated information on verified nonindigenous amphibians and reptiles in Florida. Between our most recent summary in 2012 and the end of 2015, 38 additional species are known to have been intercepted (n = 2) or introduced (n = 36). We also update the invasion stage of seven species previously reported from Florida and report that five additional taxa are now established. In total, 191 independent known introductions of 180 herpetofaunal taxa led to the establishment of 63 taxa. This suggests that one in three introduced herpetofaunal species becomes established in Florida. The pet trade represents the most common introduction pathway among these species and a single animal importer in Hollywood, Broward County, is the probable source for introduction of a quarter of all herpetofauna introduced to Florida

Proteogenomics connects somatic mutations to signalling in breast cancer

Somatic mutations have been extensively characterized in breast cancer, but the effects of these genetic alterations on the proteomic landscape remain poorly understood. We describe quantitative mass spectrometry-based proteomic and phosphoproteomic analyses of 105 genomically annotated breast cancers of which 77 provided high-quality data. Integrated analyses allowed insights into the somatic cancer genome including the consequences of chromosomal loss, such as the 5q deletion characteristic of basal-like breast cancer. The 5q trans effects were interrogated against the Library of Integrated Network-based Cellular Signatures, thereby connecting CETN3 and SKP1 loss to elevated expression of EGFR, and SKP1 loss also to increased SRC. Global proteomic data confirmed a stromal-enriched group in addition to basal and luminal clusters and pathway analysis of the phosphoproteome identified a G Protein-coupled receptor cluster that was not readily identified at the mRNA level. Besides ERBB2, other amplicon-associated, highly phosphorylated kinases were identified, including CDK12, PAK1, PTK2, RIPK2 and TLK2. We demonstrate that proteogenomic analysis of breast cancer elucidates functional consequences of somatic mutations, narrows candidate nominations for driver genes within large deletions and amplified regions, and identifies therapeutic targets

Statistical Design for Biospecimen Cohort Size in Proteomics-based Biomarker Discovery and Verification Studies

Protein biomarkers are needed to deepen our understanding of cancer biology and to improve our ability to diagnose, monitor and treat cancers. Important analytical and clinical hurdles must be overcome to allow the most promising protein biomarker candidates to advance into clinical validation studies. Although contemporary proteomics technologies support the measurement of large numbers of proteins in individual clinical specimens, sample throughput remains comparatively low. This problem is amplified in typical clinical proteomics research studies, which routinely suffer from a lack of proper experimental design, resulting in analysis of too few biospecimens to achieve adequate statistical power at each stage of a biomarker pipeline. To address this critical shortcoming, a joint workshop was held by the National Cancer Institute (NCI), National Heart, Lung and Blood Institute (NHLBI), and American Association for Clinical Chemistry (AACC), with participation from the U.S. Food and Drug Administration (FDA). An important output from the workshop was a statistical framework for the design of biomarker discovery and verification studies. Herein, we describe the use of quantitative clinical judgments to set statistical criteria for clinical relevance, and the development of an approach to calculate biospecimen sample size for proteomic studies in discovery and verification stages prior to clinical validation stage. This represents a first step towards building a consensus on quantitative criteria for statistical design of proteomics biomarker discovery and verification research